← Eichor
Condition: Hematological Malignancy Leukemia Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hematological Malignancy Leukemia Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumo
Phase 1/Phase 2 · 71 location(s) · Merck Sharp & Dohme LLC · NCT06395103MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 · 31 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05476770Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
NA · 3 location(s) · University of Miami · NCT05745285CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
Phase 1/Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06503094A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/Phase 2 · 104 location(s) · Sumitomo Pharma America, Inc. · NCT04988555Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Phase 1 · 1 location(s) · Stanford University · NCT06551584Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06043011Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Phase N/A · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT05724121A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
EARLY_Phase 1 · 1 location(s) · Affiliated Hospital of Nantong University · NCT06756321Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06904066A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04532281Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus H
Phase 2/Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07366801uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07109518A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
Phase 1 · 4 location(s) · NovaOnco Therapeutics Co., Ltd. · NCT06820268Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT06856226CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04603872Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT03702309Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT05011045Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Phase 2 · 20 location(s) · University Hospital, Clermont-Ferrand · NCT04935684Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1 · 5 location(s) · Tr1X, Inc. · NCT06462365Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04033302Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/Phase 2 · 39 location(s) · CellCentric Ltd. · NCT04068597Prospective Cohort With Hemopathy in Languedoc-Roussillon
Phase N/A · 1 location(s) · University Hospital, Montpellier · NCT02134574Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06350994
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.